Phillip Donenberg

Phillip brings more than 23 years of leadership expertise in finance, mergers and acquisitions (M&A) and operations focused in the pharmaceutical and healthcare industries. His background includes recent experience with a gene therapy company, AveXis, Inc., where he served as the Chief Financial Officer and Senior Vice President until June 15, 2018, following its acquisition by Novartis. Phillip has held leadership roles overseeing strategic transactions, financing management and accounting operations, controls and reporting processes for growing life sciences companies. Most recently, he was Chief Financial Officer and Senior Vice President of Depomed, Inc. Previously, Phillip was the Chief Financial Officer at RestorGenex Corporation from 2014 to 2016, when RestorGenex merged with Diffusion Pharmaceuticals, Inc. From 1998 to 2013, he served as the Chief Financial Officer at BioSante Pharmaceuticals, Inc. until the merger of the company with ANIP Pharmaceuticals, Inc. Phillip earned a bachelor’s degree in accountancy from the University of Illinois, and he is a Certified Public Accountant.

Phillip Donenberg is the Senior Vice President, Chief Financial Officer at AveXis, based in United States, North America. With a background in Biotechnology, Phillip Donenberg has a rich history of leadership and innovation.Phillip Donenberg studied Bachelor of Science (B.S.) Accountancy at University of Illinois Urbana-Champaign. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.